Truvestments Capital’s Aclaris Therapeutics ACRS Stock Holding History

Truvestments Capital’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$794	Hold	150	–	–	﹤0.01%	1058
2026 Q1	$563	Hold	150	–	–	﹤0.01%	1082
2025 Q4	$452	Hold	150	–	–	﹤0.01%	955
2025 Q3	$285	Hold	150	–	–	﹤0.01%	986
2025 Q2	$213	Hold	150	–	–	﹤0.01%	922
2025 Q1	$230	Hold	150	–	–	﹤0.01%	989
2024 Q4	$372	Hold	150	–	–	﹤0.01%	962
2024 Q3	$173	Buy	+150	New	+$184	﹤0.01%	904
2024 Q2	–	Sell	-150	Closed	-$186	–	229
2024 Q1	$186	Hold	150	–	–	﹤0.01%	704
2023 Q4	$158	Hold	150	–	–	﹤0.01%	773
2023 Q3	$1.03K	Hold	150	–	–	﹤0.01%	621
2023 Q2	$1.56K	Hold	150	–	–	﹤0.01%	612
2023 Q1	$1.21K	Sell	150 -148	-50%	-$1.88K	﹤0.01%	600
2022 Q4	$4.69K	Hold	298	–	–	﹤0.01%	559
2022 Q3	$5K	Hold	298	–	–	﹤0.01%	462
2022 Q2	$4K	Buy	+298	New	+$4.18K	﹤0.01%	488
2022 Q1	–	Sell	-150	Closed	-$2K	–	185
2021 Q4	$2K	Hold	150	–	–	﹤0.01%	541
2021 Q3	$3K	Hold	150	–	–	﹤0.01%	495
2021 Q2	$3K	Hold	150	–	–	﹤0.01%	501
2021 Q1	$4K	Buy	+150	New	+$2.93K	﹤0.01%	532

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Truvestments Capital's ACRS Position: Q2 2026 in Review

Truvestments Capital held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 150 shares worth $794. The position accounts for ﹤0.01% of the portfolio, ranked #1058.

Truvestments Capital first reported a position in ACRS in Q1 2021 and has held it in 20 quarters since. The position peaked at $5K in Q3 2022. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Truvestments Capital held 150 shares of Aclaris Therapeutics worth $794 as of Q2 2026.
Truvestments Capital left its Aclaris Therapeutics share count unchanged in Q2 2026.
Aclaris Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #1058 holding.
Truvestments Capital first reported a position in Aclaris Therapeutics in Q1 2021 and has held it in 20 quarters since.
Truvestments Capital's Aclaris Therapeutics position peaked at $5K in Q3 2022.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.